Events, Image Interpretation, Radiation and Radiopharmaceuticals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Events

Image Interpretation

Radiation

Radiopharmaceuticals

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,

Diagnostic

Diagnostic Radiation Oncology Radiation Clinic

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.”

Diagnose

Diagnose Diagnostic Disease Radiation

Diagnostic Imaging Brief

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Stay Connected